PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Roth Capital Downgrades PTC Therapeutics (PTCT) to Neutral
May 5, 2015 7:05 AM EDTRoth Capital downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $63.00 (from $75.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $60.84 yesterday.
... MorePTC Therapeutics (PTCT) Reports Q1 Loss Per Share of $1.15
May 4, 2015 5:02 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.15), may not compare to the analyst estimate of ($1.20). Revenue for the quarter came in at $7.48 million versus the consensus estimate of $2.97 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More